f45 glp 1 Review: What the Classes Are Really Like F45 Training Adds GLP-1s |

The purpose of this study is to determine whether or not GLP-1-associated pancreatitis risk is dose-dependent

Pfizer plans to conduct dose optimization studies in the second half of 2024 evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies

Ph 2 datathat showed weight loss of between 9.4% and 14.7% after 36 weeks on the drug compared to 2.3% for the placebo group and is currently in Ph 3

Fasting or postprandial secretin concentrations showed no significant changes

GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure

Some people who take GLP-1 drugs such as semaglutide and tirzepatide see little to no changes to their weight